



October 21, 2025

To Whom It May Concern

Company Name: Sawai Group Holdings Co., Ltd.
Representative: Mitsuo Sawai
President and Representative Director
(Securities Code: 4887 Prime Market of Tokyo Stock Exchange)
Contact: Yasushi Kora
Deputy General Manager
Group Finance Department
(Telephone Number: +81-6-6105-5823)

Notice Regarding Settlement of Lawsuit

Sawai Group Holdings Co., Ltd. (hereinafter the “Company”) hereby announces that Sawai Pharmaceutical Co., Ltd. (hereinafter “Sawai Pharmaceutical”), a consolidated subsidiary of the Company, has reached a settlement dated October 20, 2025, with Asahi Kasei Pharma Corporation (hereinafter “Asahi Kasei Pharma”) regarding a patent infringement lawsuit concerning TERIPARATIDE for Subcutaneous Injection 56.5μg [Sawai] (hereinafter “TERIPARATIDE”). The details are as follows.

1. Background of the settlement

Sawai Pharmaceutical had been requested by Asahi Kasei Pharma to cease the manufacturing and sale of its generic teriparatide product and to pay damages for patent infringement, based on the process patent (Patent No. 6025881) related to Teribone™ 56.5 μg for subcutaneous injection.

Sawai Pharmaceutical’s claim was not upheld, and on September 26, 2024, The Osaka District Court issued an order prohibiting the manufacture and sale of the product using the patented method in question and requiring the payment of damages.

An appeal was filed with the Intellectual Property High Court of Japan (hereinafter the “IP High Court”) against this ruling; however, after carefully considering the overall terms of the settlement, Sawai Pharmaceutical determined that resolving the matter through settlement was a reasonable course of action and reached an agreement accordingly.

2. Overview of the counterparty in the settlement

(1)	Name	Asahi Kasei Pharma Corporation
(2)	Address	Hibiya Mitsui Tower (TOKYO MIDTOWN HIBIYA), 1-1-2 Yurakucho, Chiyoda-ku, Tokyo
(3)	Title and Name of Representative	President, Yoshikazu Aoki

3. Contents of the settlement

Sawai Pharmaceutical paid Asahi Kasei Pharma 4 billion yen as a settlement, and Asahi Kasei Pharma waived any other claims against Sawai Pharmaceutical. Details of the settlement will not be disclosed due to confidentiality obligations contained in the settlement terms.

4. Outlook

We are presently conducting a thorough review of the impact of this matter on our financial performance. In the event that a revision of the earnings forecast for the Fiscal Year Ending March 2026 becomes necessary, we will promptly inform our stakeholders.